Jul 14, 2026 08:30AM
Jul 14, 2026 08:30AM
May 5, 2026 04:05PM
Apr 20, 2026 05:00PM
Apr 20, 2026 05:00PM
Feb 24, 2026 04:05PM
Feb 17, 2026 08:30AM Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Feb 9, 2026 11:15AM
Feb 9, 2026 11:14AM
Dec 22, 2025 07:06AM
Dec 9, 2025 07:00AM
Oct 24, 2025 08:29AM
Sep 17, 2025 04:30PM
Sep 17, 2025 04:30PM Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Jul 31, 2025 08:44AM
Jul 31, 2025 08:44AM
Jun 17, 2025 06:42AM
Jun 16, 2025 07:01AM
Jun 16, 2025 07:00AM
May 29, 2025 08:30AM
May 28, 2025 04:05PM Supernus Announces Paragraph IV ANDA Filings for Qelbree®
May 20, 2025 08:30AM
Feb 25, 2025 04:01PM
Feb 4, 2025 11:28AM
Feb 4, 2025 11:19AM
Feb 4, 2025 09:02AM
Feb 4, 2025 09:00AM
Jan 27, 2025 08:00AM Supernus Pharma (SUPN) Announces Label Update for Qelbree
Jan 27, 2025 08:00AM
Jan 27, 2025 08:00AM
Nov 4, 2024 04:05PM
Sep 24, 2024 07:30AM
Aug 19, 2024 07:01AM
Aug 19, 2024 07:00AM
Aug 1, 2024 04:30PM Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
May 23, 2024 04:06PM
May 23, 2024 04:05PM
May 8, 2024 04:05PM
May 7, 2024 10:01AM
May 7, 2024 10:00AM
Apr 8, 2024 10:10AM
Apr 8, 2024 10:09AM Stifel on Supernus Pharmaceuticals (SUPN): 'SPN-830 Approval Delayed Again, but Near-Term Impact Relatively Minor'
Apr 8, 2024 08:05AM
Apr 8, 2024 08:00AM
Feb 27, 2024 04:05PM
Feb 5, 2024 08:31AM
Feb 5, 2024 08:30AM
Nov 8, 2023 04:05PM
Nov 2, 2023 07:06AM Supernus Pharma (SUPN) Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
Nov 2, 2023 07:00AM

326,554 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All